Vancouver Location
Calgary Location

Vancouver ERS Publications

  1. Deng L, White AS, Pawlowska M, Pottinger B, Aydin J, Chow N, Tildesley HD. Cost-Benefit Analysis of Internet Therapeutic Intervention on Patients with Diabetes. Intl J Endocrinol Metabol 2015; 13(2):e22803
  2. Tildesley HD, Chow N, White AS, Pawlowska M, Ross SA. Internet Diabetes Management: A Practical Approach. Can J Diabetes 2015; 39(3):195-9.
  3. Tildesley HD, Conway ME, Deng L, Lee AM, Chan JHM, Mazanderani AB, Tildesley HG, White AS, Pawlowska M, Ross SA. The Effectiveness of Internet Intervention on 926 Patients with Diabetes for up to 30 Months. Can J Diabetes 2015; 39(3):195-9
  4. Tang TS, Digby EM, Wright AM, Chan JHM, Mazanderani AB, Ross SA, Tildesley HG, Lee AM, White AS, Tildesley HD. Real-time continuous glucose monitoring versus internet-based blood glucose monitoring in adults with type 2 diabetes: A study of treatment satisfaction. Diabetes Res and Clin Pract. 2014;106(3):481-6
  5. Tildesley HD, Po MD, Ross SA. Internet blood glucose monitoring systems provide lasting glycemic benefit in type 1 and 2 diabetes: a systematic review. Med Clin of NA. 2015; 99(1):17-33
  6. Tildesley HD, Conway MA, Ross SA, Lee AM, Chan J, Mazanderani AB, Tildesley HG, White AS. Review of the Effect of Internet Therapeutic Intervention in Patients With Type 1 and Type 2 Diabetes. Diabetes Care. 2014; 37(2):e31-e32
  7. Tildesley HD, Wright AM, Chan J, Mazanderani AB, Ross SA, Tang T, Tildesley HG, Lee AM, White AS. A Comparison of Internet Monitoring with Continuous Glucose Monitoring in Insulin-Requiring Type 2 DM. Canadian Journal of Diabetes. 2013; 37(5): 305-308
  8. Tildesley HD, Chan J, Mazanderani A, Wright A, Pottinger B, Tildesley HG. Additional Basal Rates Used in Insulin Pump Therapy Does Not Improve HbA1C in Adult Patients with Type 1 Diabetes. Canadian Journal of Diabetes. 2012; 36(1): 25-26
  9. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Perkins BA, Welsh JB, Willi SM, Wood MA for the STAR 3 Study Group. Sensor-Augmented Pump Therapy for A1C Reduction (Star 3) Study. Diabetes Care 2011; 34: 2403-2405.
  10. Ashkenas J., Ross, S., Tildesley H. Barriers to Effective Insulin Treatment: The Persistence of Poor Glycemic Control in Type 2 Diabetes. Curr Med Res Opin. 2011; 27(S3):250-253
  11. Tildesley H., Mazanderani A., Chan J., Ross S. Efficacy of A1c Reduction Using Internet Intervention in Patients with Type 2 Diabetes Treated With Insulin. Can J Diabetes. 2011; 35(3): 250-253.
  12. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, David SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA for the Star 3 Study Group. Effectiveness of Sensor-Augmented Insulin Pump Therapy in Type 1 Diabetes. New England Journal of Medicine 2010; 363: 311-320.
  13. Tildesley H, Mazanderani A, Ross S. Effect of Internet Therapeutic Intervention on HbA1C Levels in Patients with Type 2 Diabetes Treated with Insulin. Diabetes Care August 2010 33:1738-1740
  14. Tildesley H, Wise S, Mazanderani A, Fraser T, Yu E. The Effect of the Change in the Definition of Type 2 DM on Patient Demographics. International Journal of Endocrinology and Metabolism, 2009; 2: 51-55
  15. Tildesley H, Fraser T, Wise S, Mazanderani A, Aydin C, Johns K, Yu E, Bondy G. Low Prevalence in Elevated apoB levels in Type 2 Diabetes not receiving Lipid-Lowering therapy. Canadian Journal of Diabetes 2009; 33: 163-169. Winner of the Canadian Diabetes Association/Diabetes Educator Section 2010 Brian Dufton Memorial Manuscript Award
  16. Mazanderani AB, Wise SJ, Tildesley HD. Apolipoprotein B levels in adults with type 1 diabetes not receiving lipid-lowering therapy. Clinical Biochemistry 42 (2009) 1218–1221
  17. Park KY, Aydin CM, Mazanderani AB, Johnson M, Chui L, Tildesley HD. Marfan Syndrome and Early-Onset Diabetic Retinopathy: A Case Report. Int J Endocrinol Metab 2009; 1: 41-45.
  18. Tildesley H, Aydin C, Billington E, Ignaszewski AP, Strelzow JA, Wise SJ, Yu E , Bondy GP. The Effects of Thiazolidinedione Therapy on NT-proBNP Levels in Patients With Type 2 Diabetes. International Journal of Endocrinology and Metabolism. 2008
  19. Innes D, Cameron D, Farquhar A, Tildesley H, Green L, Fraser T. The Kelowna Diabetes Program:Successfully Closing the Gap Between Guidelines and Reality. Canadian Journal of Diabetes. June 2008
  20. Kreisman S, Miller R, Tildesley H, Wilcox P, Zhang H. Gender Disparities in Effects of Cystic Fibrosis Related Diabetes on Clinical Outcomes: A Matched Study. Canadian Respiratory Journal. January 2008
  21. Tildesley HD, Aydin C, Ignaszewski A, Strelzow J, Yu E, Bondy G. Sulfonylurea Therapy is Associated with Increased NT-proBNP levels in the Treatment of Type 2 Diabetes. International Journal of Cardiology. 2007.
  22. Billington E, Fraser T, Tawashy A, Tildesley H. Carbohydrate Counting vs. Sliding Scale for Insulin Dosage Estimation. Canadian Journal of Diabetes. 2007.
  23. Taylor R, Tildesley HD, Aydin C. Cost and Efficacy Comparison between Thiazolidinedione Therapy and Insulin Therapy in Patients with Type 2 Diabetes. BC Medical Journal. 2006.
  24. Johns K, Robinson C, Wilson I, Bondy G, Tildesley HD. Does the Microalbumin:Creatinine Ratio Lack Clinical Utility in Predicting Microalbuminuria? BC Medical Journal. 2006.
  25. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL , Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Ribaudo LF, Booth J, Topol RJ, for the CHARISMA Investigators. Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. New England Journal of Medicine. 2006.
  26. Johns K, Olynik C, Mase R, Kreisman S, Tildesley HD. Gestational Diabetes Mellitus Outcome in 394 Patients. Journal of Obstetrics and Gynaecology Canada. 2006.
  27. Rosenstock J,Goldstein BJ, Vinik AI, Colleen O'Neill M, Porter LE, Heise MA, Kravitz B, Dirani RG, Freed MI, the RESULT Study Group. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. Sulphonylurea Titration (RESULT) study. Diabetes, Obesity and Metabolism. 2006.
  28. Knopp RH, D’Emden M, Smilde JG, Pocock SJ on behalf of the ASPEN study group. Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects with Type 2 Diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin Dependent Diabetes Mellitus (ASPEN). 2006.
  29. Tildesley HD. Fair Pharmacare: The Myth. BC Medical Journal. 2005.
  30. McCormack J, Johns K, Tildesley H. Metformin’s Contraindications Should be Contraindicated. Canadian Medical Association Journal. 2005.
  31. Johns K, Singer J, Gill S, Kreisman S, Mase R, Pottinger B, Tildesley H. The Clinical Utility of a Non-Mydriatic Camera in a Diabetes Clinic. International Journal of Endocrinology and Metabolism. 2005.
  32. Thommasen HV, McArthur A, Tierney M, Nast S, Tildesley H. Do Rural Patients Benefit From Visits to an Urban Diabetes Teaching Centre? BC Medical Journal. 2004.
  33. Fung M, Tildesley H, Gill S. New Treatments and Treatment Philosophy for Type 1 Diabetes. BC Medical Journal. 2004.
  34. Grigg A, Thommasen H, Tildesley H, Reid R, Michalos A. Comparing Self-Related Health, Satisfaction and Quality of Life Scores Between Diabetes and Others Living in the Bella Coola Valley. Social Indicators Research. 2004.
  35. Tildesley H, Johns K. Long-Term Treatment of Type 1 Diabetes in the Out-Patient Setting: Results of 934 Patients During up to 10 Years’ Follow up. Canadian Journal of Diabetes. 2004.
  36. Patenaude J, Tildesley H, McArthur A, Thommessen A, Thommasen H. Prevalence of Diabetes Mellitus in the Aboriginal and Non-Aboriginal People Living in the Bella Coola Valley. Canadian Journal of Public Health. 2004.
  37. Cuff DF, Meneilly GS, Martin A, Ignaszewski A, Tildesley H, Frohlich JJ. Effective Exercise Modality to Reduce Insulin Resistance in Women With Type 2 Diabetes. Diabetes Care. Vol. 26, No. 11, November 2003, pp 2977-2982
  38. Leiter LA, Carr A, Belanger A, Lubin S, Ross SA, Tildesley HD, Fontaine N. DIASCAN (Diabetes Screening in Canada) Study: Prevalence of Undiagnosed Diabetes and Glucose Intolerance in Family Physicians' Offices. Diabetes Care. June 2001.
  39. Chiasson JL, Maditch L. The Synergistic Effect of Miglitol Plus Metformin Combination Therapy in the Treatment of Type 2 Diabetes. Diabetes Care. June 2001.
  40. Yoshida EM, Buczkowski AK, Sirrs SM, Elliot TG, Scudamore CH, Levin A, Tildesley HD, Landsberg DN. Post-Transplant Diabetic Ketoacidosis - A Possible Consequence of Immunosuppression with Calcineurin Inhibiting Agents: A Case Series. Transplant International. 2000.
  41. Rodby RA, Rohde RD, Clarke WR, Hunsicker LG, Anzalone DA, Atkins RC, Ritz E, Lewis EJ, for the Collaborative Study Group. The Irbesartan Type II Diabetic Nephropathy Trial: Study Design and Baseline Patient Characteristics. Nephrology Dialysis Transplant. 2000.
  42. Meneilly GS, Tildesley H, Elliot T, Palmert JP, Juneja R. Significance of GAD Positivity in Elderly Patients with Diabetes. Diabetic Medicine. 2000.
  43. Doig SM, Bebb RA, Sharpe JM, Tildelsey HD. What is the Optimal Follow-up Interval in Diabetes Education? Practical Diabetology. 1999.
  44. Forbes A, Elliott T, Tildesley H, Finegood D, Meneilly GS. Alterations in Non-Insulin-Mediated Glucose Uptake in the Elderly Patient with Diabetes. Diabetes. 1998.
  45. Zinman B, Tildesley H, Chiasson J-L, Tsui E, Strack T. Insulin Lispro in CS II: Results of a Double-Blind Crossover Study. Diabetes.1997.
  46. The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes. 1997.
  47. Meneilly GS, Elliott T, Tessior D, Hards L,Tildesley HD. NIDDM in the Elderly. Diabetes Care. 1996.
  48. Tildesley HD. Diabetes Teaching Centres in BC. BC Medical Journal.1996.
  49. Tildesley HD, Mair K, Sharpe J, Piaseczny M. Diabetes Teaching - Outcome Analysis. Patient Education and Counseling.1996.
  50. The Diabetes Control and Complications Trial Research Group. Resource Utilization and Costs of Care in the Diabetes Control and Complications Trial. Diabetes Care. 1995.
  51. Tildesley HD, Haley L, Vlahos WD, Morrison AD. Long-Term Experience in Out-Patient Treatment of Type 1 Diabetes: Results of 396 Patients after up to Six Years. Canadian Journal of Diabetes. 1995.
  52. The Diabetes Control and Complications Trial Research Group. Implementation of Treatment Protocols in the Diabetes Control and Complications Trial. Diabetes Care.1995.
  53. Breyer JA, Lawrence G, Hunsicker, Raymond PB, Lewis EJ, the Collaborative Study Group. Angiotensin Converting Enzyme Inhibition in Diabetes Nephropathy. Kidney International. 1994.
  54. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The Effect of Angiotensin Converting Enzyme Inhibition in Diabetic Nephropathy. New England Journal of Medicine. 1993.
  55. The Diabetes Control and Complications Trial Research Group. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin Dependent Diabetes Mellitus. New England Journal of Medicine. 1993.
  56. Bain R, Rhode R, Lawrence G. Hunsicker, McGill J, Corbin S, Lewis EJ, the Collaborative Study Group. A Controlled Clinical Trial of Angiotensin - Converting Enzyme Inhibition in Type 1 Diabetic Nephropathy: Study Design and Patient Characteristics. Journal of the American Society of Nephrology.1992.
  57. Rohby RA, Ali A, Rohde RD, Lewis EJ, the Collaborative Study Group for the study of Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy. Renal Scanning 99m Tc Diethylene-Triamine Pentaacetic Acid Glomerular Filtration Rate (GFR) Determination Compared with Iothalamate Clearance GFR in Diabetics. American journal of kidney diseases.1992.
  58. Sasse EA, Doumas BT, Lemann Jr J, the Collaborative Study Group. Urinary Albumin in Relation to Urinary Total Protein in Patients with Established Diabetes Nephropathy. Annals of Internal Medicine.1989.
  59. Mair K, Tildesley H. What Medical Doctors Should Know About Home Blood Glucose Monitoring. Diagnosis. 1988.
  60. Tildesley HD. The New Insulins. Medicine North America.1987.
  61. Wong C, Birmingham CL, Tildesley H. Hyperthyroidism and Bulimia: Case Report. International Journal of Eating Disorders.1987.
  62. Tildesley HD, Morrison AD. Hyperosmolar Coma and Lactic Acidosis. Current Endocrine Therapy. 1983.
  63. Tildesley HD, Toth E, Crockford PM. Syndrome of Inappropriate Secretion of Antidiuretic Hormone in Association with Chlorpromazine Ingestion. Canadian Journal of Psychiatry. 1983.